Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188057 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Domenico Cautela und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Teoriche e Applicate (DiSTA), Università Telematica eCampus, Via Isimbardi 10, 22060 Novedrate, CO, Italy. Hauptthemen laut MEDLINE: Tirzepatide, Muscle, Skeletal, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
GLP-1 receptor agonists (GLP-1RAs), dual GLP-1/GIP agonists, and the more recent triple GLP-1/GIP/glucagon agonists have transformed the treatment of type 2 diabetes mellitus (T2DM) and obesity, resulting in significant weight reduction. However, a substantial proportion (20–40%) of this weight loss is attributable to a decrease in lean mass, thereby raising concerns regarding potential sarcopenia-related risk. However, decreased lean mass is not sufficient to determine sarcopenia, which is now defined by the combined presence of decreased muscle mass, diminished strength, and impaired physical function, particularly in older or frail individuals. Thus, a further clarification of the potential mechanisms through which these molecules affect skeletal muscle is needed to optimize their use. The objective of this study is to synthesize preclinical, metabolomic, and clinical evidence on the effects of GLP-1RAs and dual/triple agonists on skeletal muscle, with a specific comparison between semaglutide and tirzepatide. This narrative review was based on a comprehensive literature search of PubMed/MEDLINE, Scopus, and Google Scholar, encompassing articles published through June 2026. This search was supplemented by manual citation tracking, which identified additional studies including preclinical and metabolomic investigations, randomized controlled trials, observational studies, and meta-analyses. Preclinical data suggest that GLP-1R/GIPR activation can positively modulate anabolic pathways, mitochondrial biogenesis, and muscle inflammation. Metabolomic evidence reveals lipid and amino acid remodeling compatible with improved mitochondrial function. Clinically, lean mass loss proportional to weight reduction is consistently observed, generally without meaningful declines in strength or performance; data for tirzepatide are more limited. Lean mass, however, is not synonymous with skeletal muscle. A paradox emerges between the presence of protective molecular signals and the clinical evidence of lean-mass loss. This phenomenon may be explained by a systemic energy/protein deficit rather than a direct catabolic effect of the drugs, although current evidence does not fully distinguish these mechanisms. The effectiveness of weight reduction should be considered a pivotal metric in clinical practice, particularly in populations susceptible to sarcopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Teoriche e Applicate (DiSTA), Università Telematica eCampus, Via Isimbardi 10, 22060 Novedrate, CO, Italy.
- Istituto di Bioscienze e Biorisorse (IBBR), CNR, Via Pietro Castellino 111, 80131 Napoli, NA, Italy.
- Scuola di Medicina e Chirurgia, Università degli studi della Campania Luigi Vanvitelli, Via Santa Maria di Costantinopoli 16, 80138 Napoli, NA, Italy.
- Dipartimento di Medicina di Precisione, Università degli studi della Campania Luigi Vanvitelli, Via de Crecchio 7, 80138 Napoli, NA, Italy.
- Dipartimento di Medicina Sperimentale, Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185 Rome, Italy.
ORCID-Profile: Domenico Cautela, Valeria Incarbona, Angela Lombardi, Bruna Laratta, Maria Luisa Balestrieri, Edoardo Mocini, Silvia Migliaccio, Daniela Tardito
Zitieren
APA
Cautela, D., Incarbona, V., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026). Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188057
Vancouver
Cautela D, Incarbona V, Lombardi A, Laratta B, Castaldo CM, Balestrieri ML, et al. Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188057
BibTeX
@article{Cautela2026,
author = {Cautela, Domenico and Incarbona, Valeria and Lombardi, Angela and Laratta, Bruna and Castaldo, Curzio Massimo and Balestrieri, Maria Luisa and Mocini, Edoardo and Migliaccio, Silvia and Tardito, Daniela},
title = {Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188057}
}
EUVIMED